CONNECT WITH US
Tech

Tech

Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines

CNBCTV18 - Tech logo

Published on

Add as a preferred source on Google
Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines

Artificial intelligence has sped up early-stage drug development work at some of the world's largest pharmaceutical companies this year, cutting by as much as half the time it takes to produce new molecules and move them into the clinic, according to their top scientists.

GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca and Sanofi all say they have moved beyond less glamorous tasks for AI like preparing regulatory filings. They are now using the technology for designing molecules, sorting out the most promising ones, and identifying safety risks.

“There is no part of the discovery through development pipeline where we are not using AI,” AstraZeneca executive Sharon Barr said.

Some of the scientists say decades of drug discovery experience and data give them an advantage over AI companies like Anthropic, which is gearing up to be a rival, partner or both, with a $1.5 trillion initial public offering this week.

In recent months, it opened its own laboratory and announced other investments, part of pushing AI to speed drug discovery.

On Thursday, Anthropic CEO Dario Amodei, at the Nasdaq before shares began trading, spoke of his father dying of a disease shortly before a cure was found.

Although clinical trials and experiments will still take time, he said, "I believe these processes can be substantially accelerated by AI. We hope that in the future, fewer families miss a cure by a few years."

Drug companies are gauging whether the upstart can succeed in tackling disease. Historically, nearly 9 out of 10 drugs developed using conventional methods fail in clinical trials.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.